The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

被引：34
|
作者：
Nazha, Aziz [1 ,2 ]
Komrokji, Rami S. [3 ]
Garcia-Manero, Guillermo [4 ]
Barnard, John [5 ]
Roboz, Gail J. [6 ]
Steensma, David P. [7 ]
DeZern, Amy E. [8 ]
Zell, Katrina [5 ]
Zimmerman, Cassie [1 ,2 ]
Al Ali, Najla [3 ]
Jabbour, Elias [4 ]
Greenberg, Molly D. [6 ]
Kantarjian, Hagop M. [4 ]
Maciejewski, Jaroslaw P. [1 ,2 ]
List, Alan F. [3 ]
Sekeres, Mikkael A. [1 ,2 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[5] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA
[6] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA
[7] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 06期
关键词：
MDS; hypomethylating agent; prognostic models; SCORING SYSTEM; CLASSIFICATION; AZACITIDINE; PROPOSAL;
D O I：
10.3324/haematol.2015.140962
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E224 / E227
页数：4
相关论文
共 43 条
  • [1] Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure
    Patel, Sagar S.
    Sekeres, Mikkael A.
    Nazha, Aziz
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2532 - 2539
  • [2] Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
    Carraway, Hetty E.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 470 - 477
  • [3] Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes
    Chien, Kelly
    Kim, Kunhwa
    Li, Ziyi
    Shamanna, Rashmi Kanagal
    Ong, Faustine
    Bravo, Guillermo Montalban
    Kadia, Tapan
    Jabbour, Elias
    Pemmaraju, Naveen
    Hammond, Danielle
    Short, Nicholas
    Ravandi, Farhad
    Alvarado, Yesid
    Pierce, Sherry
    Dong, Xiao Qin
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S311 - S311
  • [4] A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure
    Swaminathan, Mahesh
    Borthakur, Gautam
    Kadia, Tapan M.
    Ferrajoli, Alessandra
    Alvarado, Yesid
    Pemmaraju, Naveen
    Bodden, Kristy
    Yearby, Brittany
    Konopleva, Marina
    Khoury, Joseph
    Bueso-Ramos, Carlos
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2207 - 2213
  • [5] Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
    Zeidan, Amer M.
    Kharfan-Dabaja, Mohamed A.
    Komrokji, Rami S.
    CURRENT OPINION IN HEMATOLOGY, 2014, 21 (02) : 123 - 130
  • [6] Practical Recommendations for Hypomethylating Agent Therapy of Patients With Myelodysplastic Syndromes
    Steensma, David P.
    Stone, Richard M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 389 - +
  • [7] Outcome After Hypomethylating Agents Failure in Patients With IDH1 Mutated Myelodysplastic Syndromes
    Abuhelwa, Ziad
    Al Ali, Najla
    Xie, Zhuoer
    Chan, Onyee
    Seongseok, Yun
    Kuykendall, Andrew
    Walker, Alison
    Lancet, Jeffrey
    Padron, Eric
    Sallman, David
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S391 - S391
  • [8] Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
    Darbaniyan, Faezeh
    Zheng, Hong
    Kanagal-Shamanna, Rashmi
    Lockyer, Pamela
    Montalban-Bravo, Guillermo
    Estecio, Marcos
    Lu, Yue
    Soltysiak, Kelly A.
    Chien, Kelly S.
    Yang, Hui
    Sasaki, Koji
    Class, Caleb
    Ganan-Gomez, Irene
    Do, Kim-Anh
    Garcia-Manero, Guillermo
    Wei, Yue
    EXPERIMENTAL HEMATOLOGY, 2022, 115 : 44 - 53
  • [9] A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy
    Yalniz, Fevzi F.
    Berdeja, Jesus G.
    Maris, Michael B.
    Lyons, Roger M.
    Reeves, James A., Jr.
    Essell, James H.
    Patel, Prapti
    Sekeres, Mikkael
    Hughes, Amanda
    Mappa, Silvia
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (03) : 404 - 412
  • [10] Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes
    Kim, Kunhwa
    Ong, Faustine
    Li, Ziyi
    Shamanna, Rashmi Kanagal
    Bravo, Guillermo Montalban
    Kadia, Tapan
    Jabbour, Elias
    Pemmaraju, Naveen
    Hammond, Danielle
    Short, Nicholas
    Ravandi, Farhad
    Alvarado, Yesid
    Pierce, Sherry
    Dong, Xiao Qin
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Chien, Kelly
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S313 - S314
12345